149 results about "Topical drug" patented technology

A device to treat infections, diseases, and disorders. The device can be used to treat part of a larger organism such as using the device to kill cancerous cells in humans or animals or to kill parasites. The invention can also may be used to treat fungal and bacterial nail infections of the hands and feet which are difficult to treat with oral and topical drugs.

A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.

A process and apparatus (invention) permitting the distribution of micro or submicro liter or gram (exceptionally small) quantities of liquids and powders, (hereafter materials) in patterns and quantities that are especially well-suited for ophthalmologic patient self-application of drugs to his own eye(s) with substantially no overdose. The invention is thus also highly beneficial in those many topical drug applications where overdoses should be avoided. This is particularly applicable for the eye, where overdoses can have many deleterious medical consequences. Use of the invention permits exceptionally small doses of ophthalmologic drugs. Moreover, it also permits the repeatability of the quantity size of the materials chosen for delivery. In the case of drugs, particularly opthomologic drugs, this means that the invention permits the repeated multiple distribution of the same chosen drug / carrier quantity resulting in a uniform repeatable dosage. Variation of dose from one application to another is very unacceptable. The preferred apparatus of the invention employs a venturi configuration inventively modified which uses gas under pressure to pump exceptionally small quantities of material from a reservoir for delivery. In especially preferred embodiments of the invention, said reservoir is pressurized by at least a quantity of gas at somewhat above atmospheric. prior to the removal of any material by pumping.

This invention relates to pouch or pledget delivery system having an apertured film or fabric covering which assists in evenly and safely distributing topical medicaments.

Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.

Topical drug compositions of this invention contain delayed type contact sensitizing haptens in a unique non-flowable, non-toxic, non-volatile, anhydrous gel composition to achieve retained site application on warts and other human papilloma virus (HPV) skin infections. The preferred gelled compositions contain, but are not limited to, the sensitizing haptens, squaric acid dibutylester and diphenylcyclopropenone in optimized blends of Polysorbate 80, Isopropyl myristate uniquely gelled with Polyoxyl 40 stearate to form a penetrant of keratinized epitheliiuim of warts for direct application wherein virucidal pharlacologic action is induced by Th-1 cell mediated immune responses with resultant releases of CD4 helper T cells, CD8 killer T cells and cytokines to attack the human papilloma viruses. The commonly used vehicles with these contact sensitizers are acetone, petrolatum, or water containing emulsion creams which do not have the capacity to penetrate the keratinized wart surfaces and are therefore minimally effective in treating warts.

Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.

A water-in-oil emulsion is provided in which the lipophilic phase of the emulsion contains a silicone fluid and an emulsifier, a hydrophilic phase, and a pharmaceutically active compound. The active pharmaceutical ingredient is dissolved or dispersed in the emulsion and is partitioned in the emulsion so that all or a portion of the amount of the chemical compound dissolved or dispersed in the emulsion is dissolved or dispersed in the aqueous phase of the emulsion. The emulsion of the invention provides increased penetration into skin of the chemical compound dissolved or dispersed in the aqueous phase.

Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.

The invention relates to a freeze-dried excipient and a matched solvent packaging double-cavity bag, in particular to a double-cavity bag which enables a freeze-dried excipient applied to foods or health foods or oral drugs or topical drugs or cosmetics and a solvent to be independently stored and used in the same package and prepared to be readily available. The packaging double-cavity bag for the freeze-dried excipient has the advantages of protecting the stability of active ingredients, achieving single-dose packaging, being convenient to carry and use, avoiding contamination, lowering the cost and the like.

The present invention relates to cyclic ether side group-containing amphiphilic polymer lyophilized powder and a composition thereof, and applications of the composition, wherein the lyophilized powder is the lyophilized powder of a cyclic ether side group-containing amphiphilic polymer or the drug-loaded lyophilized powder adopting a cyclic ether side group-containing amphiphilic polymer as an auxiliary material, the amphiphilic polymer is selected from one or a plurality of ABA type and BAB type amphiphilic block copolymers comprising a degradable polyester A containing a 1,4,8-trioxaspiro[4.6]-9-undecanone (TOSUO) unit and a polyethylene glycol block B, and the polyester A is a copolymer of caprolactone, lactide, glycolide and TOSUO. According to the present invention, the lyophilized powder can be rapidly dispersed into an aqueous medium at a temperature of 4-25 DEG C to form a flowable liquid and can be rapidly gelated under the body temperature environment; and the pyrogen-free powder injection after the sterilization treatment can be used for the clinical topical drug administration application, is sued for the topical drug administration on the intratumoral position, the peritumoral position, the thoracic cavity, the peritoneal cavity, the Intravesical position, the position in the liver, the intranasal position, the intraocular position, the intravaginal position and other positions, and the drug can be subjected to long-acting slow-release.

The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and / or pharmaceutical active.

The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte andmethods of their use.

This invention relates to a topical pharmaceutical composition comprising a combination of methotrexate, alpha bisabolol and allantoin; a process for producing the same and the use of the composition in the treatment of plaque psoriasis (psoriasis vulgaris), atopic dermatitis and chronic eczema. The composition of this invention can be used alone or in combination with other topical or systemic therapies. The present invention further discloses a process for producing the pharmaceutical composition.

A topical drug for treating tympanitis and its producing method belong to medicine technical field, which is used for treating the simple chronic suppurative otitis media with a project that: having the furazolidone 1.8-2.2, vitamin E 0.9-1.1, benne oil 25-65 as material, preparing, milling, mixing, bottling, then getting the topical drug liquid. The invention collects the treatment advantages of the chinese and foreign medicine to the local fester induced by bacillosis, selects the furazolidone, benne oil, vitamin E in proportion to produce topical drug for treating tympanitis, preferred chronic suppurative otitis media. Clinic application indicates that the drug is used for treating simple chronic suppurative otitis media and taking one time a day and working three day in a treatment period. It could properly prolong the treatment time with 100% efficiency to the patent with a long course of disease and a severe symptom. The invention also has a simple medication, a low toxic side effect, a low price, a strong patent compliance and etc.